BioSpace News Archive

Business

Takeda Bets $4B Upfront on Nimbus’ TYK2 Inhibitor

On the heels of positive Phase IIb data in plaque psoriasis, Takeda is acquiring both the therapy and Nimbus Lakshmi, a wholly owned subsidiary, in a potentially $6 billion deal.

December 13, 2022
·
2 min read
·
Mark Terry
Drug Development

Moderna and Merck’s mRNA Cancer Vaccine Aces Advanced Melanoma Study (Updated)

An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.

December 13, 2022
·
2 min read
·
Tristan Manalac
FDA

Mirati Challenges Amgen in KRAS Space with FDA Accelerated Approval

Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.

December 13, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Novel Capabilities of Innovative AntibodyPlus Therapeutics Go Beyond ADCs

Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.

December 13, 2022
·
7 min read
·
Gail Dutton
Business

GSK Strikes $3.3B Oligonucleotide Pact with Wave Life Sciences

GSK bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.

December 13, 2022
·
3 min read
·
Alex Keown
Business

Flagship-Backed Biotech Uses Naturally-Occurring Molecules to Treat Chronic Disease (Updated)

Flagship Pioneering has committed $50 million to Montai Health, a biotech that aims to develop therapies for chronic diseases using molecules already found in nature.

December 13, 2022
·
2 min read
·
Rosemary Scott
Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

Spexis AG today announced results from an in vitro study evaluating the effects of combining Spexis’ potent CXCR4 inhibitor balixafortide (BLX) with several conventional or targeted therapies on the market in B-cell lymphoma models.

December 13, 2022
·
5 min read
AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera from AOP Health´s CONTINUATION-PV study and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health presented at ASH 2022 Annual Meeting, New Orleans, USA.

December 13, 2022
·
4 min read
BioForest

NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the company’s CosMx™ Spatial Molecular Imager has been recognized by The Scientist magazine as one of the Top 10 Innovations of the 2022.

December 13, 2022
·
4 min read
Deals

Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, announced that it has entered into a definitive agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump.

December 13, 2022
·
6 min read